Book.
1930 - Gale Group | Foreign Rel Latin Am and CS
James Witowsky, Gary L. Johnson,
... H., and Hunter, T. (2002) Mol. Cell 9, 945–956). MEKK1 kinase activity is required for ubiquitylation ... H., and Hunter, T. (2002) Mol. Cell 9, 945–956). MEKK1 kinase activity is required for ubiquitylation ... M.H. Hunter T. Mol. Cell. 2002; 9: 945-956Abstract Full Text Full Text PDF PubMed Scopus ( ... M.H. Hunter T. Mol. Cell. 2002; 9: 945-956Abstract Full Text Full Text PDF PubMed Scopus ( ... M.H. Hunter T. Mol. Cell. 2002; 9: 945-956Abstract Full Text Full Text PDF PubMed Scopus ( ... M.H. Hunter T. Mol. Cell. 2002; 9: 945-956Abstract Full Text Full Text PDF PubMed Scopus ( ...
Tópico(s): PI3K/AKT/mTOR signaling in cancer
2003 - Elsevier BV | Journal of Biological Chemistry
Book.
0000 - Gale Group | Foreign Rel Latin Am and CS
... The predominant isolate in the cohort, designated FeLV-945, was identified exclusively in disorders of non-T-cell origin. The FeLV-945 LTR was shown to contain a unique 21- ... complex. Oncogene utilization during tumor induction by FeLV-945 was studied using a recombinant Moloney murine leukemia virus containing the FeLV-945 LTR. This approach identified novel loci of common ... of PI-3Kgamma. Mutational changes identified in FeLV-945 SU were shown not to alter receptor usage ... determine whether the unique sequence elements of FeLV-945 influence the course of infection and disease in ...
Tópico(s): Virus-based gene therapy research
2008 - Elsevier BV | Veterinary Immunology and Immunopathology
Directory of Open Access Books (DOAB)
Book.
0000 - Gale Group | Foreign Rel Latin Am and CS
Louis J. Aronne, Nick Finer, Priscilla Hollander, Richard D. England, Solomon S. Klioze, Robert Chew, Robert J. Fountaine, Craig M. Powell, John D. Obourn,
... to assess the efficacy and safety of CP-945,598 for weight loss and weight-loss maintenance. ... However, the 2-year trials and the CP-945,598 development program were terminated before completion due ... American studies were randomized to 10-mg CP-945,598 (n = 360; 718); 20-mg CP-945,598 (n = 534, 1,084) and placebo (n = ... 975 participants were randomized to 10-mg CP-945,598 (n = 318); 20-mg CP-945,598 (n = 320); and placebo (n = 337) in ... each trial. One year of treatment with CP-945,598 resulted in a dose-related mean percentage ...
Tópico(s): Dietary Effects on Health
2011 - Wiley | Obesity
Book.
0000 - Gale Group | Foreign Rel Latin Am and CS
Chandtip Chandhasin, Patricia N. Coan, Ivona Pandrea, Chris K. Grant, Patricia Lobelle‐Rich, Adriane Puetter, Laura S. Levy,
... gene have been linked to disease outcome. FeLV-945 was previously identified as a natural isolate predominant ... nonneoplastic diseases in a geographic cohort. The FeLV-945 LTR was shown to contain unique repeat elements, ... bp triplication downstream of the enhancer. The FeLV-945 SU gene was shown to encode mutational changes ... the LTR and envelope (env) gene of FeLV-945, or the LTR only, was substituted for homologous ... A/61E. The results showed that the FeLV-945 LTR determined the kinetics of disease. Substitution of ...
Tópico(s): Animal Disease Management and Epidemiology
2005 - American Society for Microbiology | Journal of Virology
Book.
0000 - Gale Group | Foreign Rel Latin Am and CS
Dagmar Kulms, Birgit Pöppelmann, Thomas Schwarz,
... M. Science. 1996; 274: 1194-1197Crossref PubMed Scopus (945) Google Scholar) reported for the first time that ... M. Science. 1996; 274: 1194-1197Crossref PubMed Scopus (945) Google Scholar, 19.Sheikh M.S. Antinore M. ... M. Science. 1996; 274: 1194-1197Crossref PubMed Scopus (945) Google Scholar, 22.Aragane Y. Kulms D. Metze ... M. Science. 1996; 274: 1194-1197Crossref PubMed Scopus (945) Google Scholar). Thereafter cells were washed with PBS, ... M. Science. 1996; 274: 1194-1197Crossref PubMed Scopus (945) Google Scholar). However, in contrast to UV, osmotic ...
Tópico(s): Genomics, phytochemicals, and oxidative stress
2000 - Elsevier BV | Journal of Biological Chemistry
IEEE Xplore
Book.
1935 - Gale Group | Foreign Rel Latin Am and CS
Michelle Leigh Steinhilb, Raymond Scott Turner, James R. Gaut,
... Dale Schenk (Elan Pharmaceuticals). The rabbit polyclonal antibody, 945, was raised against a synthetic peptide corresponding to ... the cell lysate supernatants by immunoprecipitation using the 945 rabbit antisera to the carboxyl terminus of APP. ... noted, lysates were incubated with 4 μl of 945 antisera for 90 min at 4 °C and ... using the ECL system (Amersham Pharmacia Biotech). The 945 and 931 antisera were used as capture antibodies ... s instructions. The anti-APP COOH-terminal antibody, 945, was affinity-purified with the same 20-amino ...
Tópico(s): Amyloidosis: Diagnosis, Treatment, Outcomes
2001 - Elsevier BV | Journal of Biological Chemistry
PubMed Central (PMC)
This Photo Captures Matsushima Beach as Seen from Kyogashima Island. The Kanrantei Teahouse in the Momohama Period (Late 16th Century) Architecture Style, ...
0000 - Gale Group | NCCO Photography
Yasir Y. Elamin, Misako Nagasaka, Elaine Shum, Lyudmila Bazhenova, D. Ross Camidge, Byoung Chul Cho, Enriqueta Felip, Kōichi Goto, Chia‐Chi Lin, Zofia Piotrowska, David Planchard, Julia Rotow, David R. Spigel, Daniel Shao-Weng Tan, Tatsuya Yoshida, Anna Minchom, Adrianus J. de Langen, Terufumi Kato, Alena Zalutskaya, Karen L. Reckamp,
... mo in pts with exon 19 deletions). BLU-945 is an investigational, next-generation, oral tyrosine kinase ... selective against EGFR wild type (WT). Preclinically, BLU-945 in combination (combo) with OSI had enhanced potency ... in-human phase 1/2 study of BLU-945 monotherapy (mono) or combo with OSI. Methods: In ... 1; treated with ≥1 EGFR TKI) received BLU-945 mono starting at 25 mg QD. Pts progressing on OSI could receive BLU-945 with 80 mg OSI starting at 50% of the highest safe BLU-945 mono dose. Each dose escalation followed a Bayesian ...
Tópico(s): Colorectal Cancer Treatments and Studies
2023 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Book.
1930 - Gale Group | Foreign Rel Latin Am and CS
Sun Min Lim, Chae Won Park, Zhuo Zhang, Rich Woessner, Tom Dineen, Faith Stevison, John Hsieh, Meredith S. Eno, Doug Wilson, John Campbell, Caitlin Utt, Faris Albayya, Nicolas Lamontagne, Marion Dorsch, Klaus P. Hoeflich, Byoung Chul Cho, Stefanie S. Schalm,
... for patients with EGFR+/T790M/C797S NSCLC. BLU-945 is a potent and highly selective inhibitor of ... models. Method: In vivo antitumor activity of BLU-945 was evaluated in engineered triple mutant cell line- ... by bioluminescence imaging. Results: Oral administration of BLU-945 to tumor-bearing mice showed potent EGFR pathway ... C797S PDX model. In addition, combination of BLU-945 with osimertinib showed enhanced antitumor activity compared with ... PDX model. Pharmacodynamic assays revealed treatment with BLU-945 resulted in marked inhibition of EGFR, AKT and ...
Tópico(s): Colorectal Cancer Treatments and Studies
2021 - American Association for Cancer Research | Cancer Research
Book.
1934 - Gale Group | Foreign Rel Latin Am and CS
Luz Tavera, Stefanie S. Schalm, John Campbell, Jian Guo, Clare Medendorp, Maxine Chen, Faris Albayya, Tom Dineen, Zhuo Zhang, Maria S. Iliou, Ebby Job, Nisha Perez, Yoav Timsit, Scott Wardwell, Katie McGinn, Richard Woessner, Chiara Conti,
... a significant unmet need in this population. BLU-945 and BLU-701 are investigational, reversible, selective, and ... studies previously demonstrated the antitumor activity of BLU-945 against EGFR L858R/T790M and EGFRm/T790M/C797S ... conducted to evaluate the antitumor activity of BLU-945 and BLU-701, as single agents and in ... METHODS: The in vivo antitumor activities of BLU-945 and BLU-701, as single-agents or in ... RESULTS: Oral daily administration of single-agent BLU-945 and single-agent BLU-701 resulted in sustained ...
Tópico(s): Cancer therapeutics and mechanisms
2022 - American Association for Cancer Research | Cancer Research
OAPEN Free
Book.
0000 - Gale Group | Foreign Rel Latin Am and CS
Zhuang Miao, Hao Sun, Jennifer L. Liras, Chandra Prakash,
... 6-yl)-4-(ethylamino)-piperidine-4-carboxamide (CP-945,598), an orally active antagonist of the cannabinoid ... 25-mg oral dose of [ 14 C]CP-945,598 to healthy human subjects. Serial blood samples ... excreted in the feces. The absorption of CP-945,598 in humans was slow with T max ... drug in the combined excreta, suggesting that CP-945,598 is extensively metabolized. The primary metabolic pathway of CP-945,598 involved N-de-ethylation to form an ... 1.1-fold greater than that of CP-945,598. M1, M2, and M9 accounted for 5. ...
Tópico(s): Psychedelics and Drug Studies
2011 - American Society for Pharmacology and Experimental Therapeutics | Drug Metabolism and Disposition